A CRISPR/Cas9 genome editing pipeline in the EndoC-βH1 cell line to study genes implicated in beta cell function
Open Access
- 8 October 2019
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
Abstract
Type 2 diabetes (T2D) is a global pandemic with a strong genetic component, but most causal genes influencing the disease risk remain unknown. It is clear, however, that the pancreatic beta cell is central to T2D pathogenesis. In vitro gene-knockout (KO) models to study T2D risk genes have so far focused on rodent beta cells. However, there are important structural and functional differences between rodent and human beta cell lines. With that in mind, we have developed a robust pipeline to create a stable CRISPR/Cas9 KO in an authentic human beta cell line (EndoC-βH1). The KO pipeline consists of a dual lentiviral sgRNA strategy and we targeted three genes (INS, IDE, PAM) as a proof of concept. We achieved a significant reduction in mRNA levels and complete protein depletion of all target genes. Using this dual sgRNA strategy, up to 94 kb DNA were cut out of the target genes and the editing efficiency of each sgRNA exceeded >87.5%. Sequencing of off-targets showed no unspecific editing. Most importantly, the pipeline did not affect the glucose-responsive insulin secretion of the cells. Interestingly, comparison of KO cell lines for NEUROD1 and SLC30A8 with siRNA-mediated knockdown (KD) approaches demonstrate phenotypic differences. NEUROD1-KO cells were not viable and displayed elevated markers for ER stress and apoptosis. NEUROD1-KD, however, only had a modest elevation, by 34%, in the pro-apoptotic transcription factor CHOP and a gene expression profile indicative of chronic ER stress without evidence of elevated cell death. On the other hand, SLC30A8-KO cells demonstrated no reduction in KATP channel gene expression in contrast to siRNA silencing. Overall, this strategy to efficiently create stable KO in the human beta cell line EndoC-βH1 will allow for a better understanding of genes involved in beta cell dysfunction, their underlying functional mechanisms and T2D pathogenesis.Funding Information
- Medical Research Council (MR/L020149/1)
- Horizon 2020
- Wellcome Trust (095101, 200837)
- National Institutes of Health (U01-DK105535)
- NIHR Oxford Biomedical Research Centre
- National Institutes of Health (U01-DK085545)
This publication has 76 references indexed in Scilit:
- RNA-Guided Human Genome Engineering via Cas9Science, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteriaProceedings of the National Academy of Sciences of the United States of America, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetesNature Genetics, 2012
- Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancyDiabetologia, 2010
- Pancreatic β Cells Require NeuroD to Achieve and Maintain Functional MaturityCell Metabolism, 2010
- Proliferation of sorted human and rat beta cellsDiabetologia, 2007
- Insulin gene mutations as a cause of permanent neonatal diabetesProceedings of the National Academy of Sciences of the United States of America, 2007
- A genome-wide association study identifies novel risk loci for type 2 diabetesNature, 2007